Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.66 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | FABP3 | P05413 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.58 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.54 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021533 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL3502856 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL160176 | 0.98 | SMN1; SMN2 (0.63) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL747961 | 0.94 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL672430 | 0.94 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL326877 | 0.94 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL326926 | 0.94 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL5698359 | 0.94 | SMN1; SMN2 (0.74) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| Trifluoromethanesulfonic Acid SCHEMBL184536 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3 | |
| SCHEMBL18628315 | 0.91 | S1PR1 (0.61) | SMN1; SMN2NR5A2NR5A1ALDH1A1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148169-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | HDT BIO CORP. (US) | 2024-07-11 | — | — | WO | claimed |
| WO-2024144348-A1 | VACCINE COMPOSITION COMPRISING IONIC COMPLEX OF CATIONIC MOLECULAR TRANSPORTER AND MRNA | 주식회사 바이오파마 | 2024-07-04 | — | — | WO | claimed |
| US-20240216274-A1 | DRIED NANOPARTICLE COMPOSITIONS | HDT BIO CORP. | 2024-07-04 | — | — | US | claimed |
| US-20240216493-A1 | CANCER THERAPY COMPOSITIONS AND USES THEREOF | HDT BIO CORP. | 2024-07-04 | — | — | US | claimed |
| US-20240207186-A1 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR LOADING RNA | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2024-06-27 | — | — | US | claimed |
| WO-2024128719-A1 | METHOD FOR DETECTING HIGH SENSITIVITY OF CANCER CELL-DERIVED EXTRACELLULAR VESICLE GENE BY USING FUSION REACTION WITH LIPOSOMES | 기초과학연구원 | 2024-06-20 | — | — | WO | claimed |
| WO-2024119074-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024119017-A1 | SYNTHETIC SINGLE STRANDED NUCLEIC ACID COMPOSITIONS AND METHODS THEREOF | GENERATION BIO CO. (US) | 2024-06-06 | — | — | WO | claimed |
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | EYEGENE INC. (KR) | 2024-05-23 | — | — | US | claimed |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | EYEGENE INC. (KR) | 2024-05-09 | — | — | US | claimed |
| EP-1833838-A2 | CATIONIC LIPOSOMES COMPRISING A CHARGE NEUTRAL COMPOUND AND A CATIONIC PHOSPHOLIPID | Applera Corporation, Applied Biosystems Group (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1704244-A2 | METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF ENZYME ACTIVITY IN CELLS | Applera Corporation, Applied Biosystems Group (US) | 2006-09-27 | — | — | EP | claimed |
| EP-0819758-B1 | Cationic vehicle: DNA complexes and their use in gene therapy | MIXSON ARCHIBALD JAMES (US) | 2006-09-20 | — | — | EP | claimed |
| US-20060159738-A1 | Cationic liposomes and methods of use | APPLERA CORPORATION (US) | 2006-07-20 | — | — | US | claimed |
| WO-2006065960-A2 | CATIONIC LIPOSOMES COMPRISING A CHARGE NEUTRAL COMPOUND AND A CATIONIC PHOSPHOLIPID | APPLERA CORPORATION (US) | 2006-06-22 | — | — | WO | claimed |
| US-20060045910-A1 | Preserved fusogenic vesicles | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2006-03-02 | — | — | US | claimed |
| US-20050244907-A1 | Methods, compositions, and kits for analysis of enzyme activity in cells | APPLERA CORPORATION | 2005-11-03 | — | — | US | claimed |
| WO-2005059163-A2 | METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF ENZYME ACTIVITY IN CELLS | APPLERA CORPORATION (US) | 2005-06-30 | — | — | WO | claimed |
| US-20020160505-A1 | Modulation of cellular adhesion with lipid membrane micro-arrays | ENERGY, UNITED STATES DEPARTMENT OF | 2002-10-31 | — | — | US | claimed |
| WO-2000009071-A2 | A NOVEL LIPOSOMAL FORMULATION USEFUL IN TREATMENT OF CANCER AND OTHER PROLIFERATION DISEASES | ALL INDIA INSTITUTE OF MEDICAL SCIENCES (IN) | 2000-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060045910-A1 | Preserved fusogenic vesicles | NSF, FUS, HNRNPDL | SMN1; SMN2 450/4885NR5A2 4385/4885NR5A1 3744/4885 |
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | ACE2, SARS1, RBM22 | SMN1; SMN2 480/4885NR5A2 2098/4885NR5A1 3502/4885 |
| US-20060159738-A1 | Cationic liposomes and methods of use | AGBL2, CLTB, CLTC | SMN1; SMN2 4586/4885NR5A2 4629/4885NR5A1 4692/4885 |
| US-20240207186-A1 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR LOADING RNA | SARNP, SYNCRIP, AUP1 | SMN1; SMN2 2976/4885NR5A2 4023/4885NR5A1 3168/4885 |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | RTCB, RRP1B, PRPF6 | SMN1; SMN2 817/4885NR5A2 4748/4885NR5A1 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.